5mgr
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Human receptor NKR-P1 in glycosylated form, extracellular domain== | |
| - | + | <StructureSection load='5mgr' size='340' side='right' caption='[[5mgr]], [[Resolution|resolution]] 1.80Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[5mgr]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5MGR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5MGR FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5mgr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5mgr OCA], [http://pdbe.org/5mgr PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5mgr RCSB], [http://www.ebi.ac.uk/pdbsum/5mgr PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5mgr ProSAT]</span></td></tr> |
| + | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/KLRB1_HUMAN KLRB1_HUMAN]] Plays an inhibitory role on natural killer (NK) cells cytotoxicity. Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide. Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3. Acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope as well as to the N-acetyllactosamine epitope. Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells.<ref>PMID:16455998</ref> <ref>PMID:16925668</ref> <ref>PMID:8077657</ref> | ||
| + | == References == | ||
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Blaha, J]] | ||
| + | [[Category: Dohnalek, J]] | ||
| + | [[Category: Harlos, K]] | ||
| + | [[Category: Hasek, J]] | ||
| + | [[Category: Koval, T]] | ||
| + | [[Category: Skalova, T]] | ||
| + | [[Category: Stransky, J]] | ||
| + | [[Category: Vanek, O]] | ||
| + | [[Category: Yuguang, Z]] | ||
| + | [[Category: Ctl fold]] | ||
| + | [[Category: Immune system]] | ||
| + | [[Category: Natural killer cell]] | ||
| + | [[Category: Receptor]] | ||
Revision as of 05:47, 6 June 2018
Human receptor NKR-P1 in glycosylated form, extracellular domain
| |||||||||||
Categories: Blaha, J | Dohnalek, J | Harlos, K | Hasek, J | Koval, T | Skalova, T | Stransky, J | Vanek, O | Yuguang, Z | Ctl fold | Immune system | Natural killer cell | Receptor
